explore -WSS

explore

author：comprehensive 2025-10-01 18:35:17 - browse：536

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Steward Health Care has deal to sell doctor network to UnitedHealth

WSS

Readout LOUD podcast: mifepristone case, GLP

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Roivant's CEO is a star, but biotech's black hole persists

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

The problems with dementia villages

FDA clears Verve to begin U.S. study of gene

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Activists slam private health insurers over coverage restrictions

Abortion pill Supreme Court ruling could impact entire drug industry

Drug repurposing or repositioning? The language matters

Washington mulls new rules to avert another Change Healthcare

How one medical school became remarkably diverse

Steward Health Care has deal to sell doctor network to UnitedHealth

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: How researchers deal with rejection

As demand for Covid shots wanes, Moderna seeks its next success

Will generative AI in health care meet the fate of IBM's Dr. Watson?

hotspot

States should stop sabotaging methadone treatment reform

CZI to create biohub to build anti

Steward Health Care has deal to sell doctor network to UnitedHealth

STAT Readout Newsletter: Biotech news today

Study says nonprofit hospitals fall short in charity care spending

Washington mulls new rules to avert another Change Healthcare

hotspot

explore

entertainment

Wikipedia